By binding to GLUT2 on pancreatic cells and interacting with CTLA-4 on autoreactive T cell, it can promote tolerance and delay the onset of diabetes without apparent adverse effects, thus providing a potential therapeutic strategy for T1D (52). This evidence concerns the gene SLC2A2 and type 1 diabetes mellitus.